Please use this identifier to cite or link to this item:
Title: Robust sars?cov?2 antibody responses in asian covid?naïve subjects 180 days after two doses of bnt162b2 mrna covid?19 vaccine
Authors: Lau, Chin-Shern
Phua, Soon Kieng
Liang, Ya-Li
Oh, Helen May-Lin
Aw, Tar-Choon 
Keywords: MRNA vaccines
Neutralizing antibodies
Spike antibodies
Issue Date: 25-Oct-2021
Publisher: MDPI
Citation: Lau, Chin-Shern, Phua, Soon Kieng, Liang, Ya-Li, Oh, Helen May-Lin, Aw, Tar-Choon (2021-10-25). Robust sars?cov?2 antibody responses in asian covid?naïve subjects 180 days after two doses of bnt162b2 mrna covid?19 vaccine. Vaccines 9 (11) : 1241. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Background: Subjects with previous COVID?19 have augmented post?vaccination re-sponses. However, the antibody response in COVID?naïve subjects from Southeast Asia is not well known. Methods: 77 COVID?naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T?Ab), IgG, IgM) and neutralizing antibodies (N?Ab)] pre?vaccination, 10 days after dose 1, and 20/40/60/90/120/150/180 days after dose 2. Results: 10 days after dose 1, 67.6% (48/71)/69.0% (49/71) were T?Ab/IgG positive; only 15.5% (11/71)/14.1% (10/71) were N?Ab/IgM positive. While all (100%) subjects had brisk T?Ab, IgG and N?Ab antibody responses 20 days after complete vaccina-tion, only 79.1% (53/67) were IgM positive. At 180 days (n = 8), T?Ab/IgG/N?Ab were still reactive (lowest T?Ab 186 U/mL, IgG 617 AU/mL, N?Ab 0.39 ?g/mL), but IgM was negative in all samples. Spike antibody thresholds of T?Ab 74.1 U/mL (r = 0.95) and IgG 916 AU/mL (r = 0.95) corresponded to N?Ab reactivity (>0.3 ?g/mL). Non?linear regression analysis showed that N?Ab would decrease to 0.3 ?g/mL by 241 days, whereas T?Ab/IgG would need 470/163 days to reach titers of T?Ab/IgG associated with a N?Ab 0.3 ?g/mL (76.4 U/mL and 916 AU/mL respectively). Conclusions: The antibody responses of T?Ab, IgG and N?Ab remain high and durable even at 180 days. N?Ab titers are expected to remain reactive up to 241 days post?vaccination. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Source Title: Vaccines
ISSN: 2076-393X
DOI: 10.3390/vaccines9111241
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_vaccines9111241.pdf1.58 MBAdobe PDF




checked on Nov 21, 2022

Page view(s)

checked on Nov 17, 2022

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons